CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 11,140 enrolled
Drug / intervention
Perindopril-indapamide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00145925
NCT00145925Phase 3Completed
CompareCT.gov

ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation

The George Institute·interventional·Posted Sep 5, 2005·Updated Apr 11, 2025

In Brief

A Phase 3 clinical trial evaluating Perindopril-indapamide and Gliclazide MR-based glucose lowering for Diabetes Mellitus, Type 2. Completed, enrolled 11,140 participants across 5 sites in 5 countries.

Detailed Summary

The purpose of this study is to provide information on the risks and benefits of routine blood pressure lowering (regardless of blood pressure level), and intensive lowering of blood glucose levels, in patients with Type 2 diabetes at high risk of cardiovascular events. The major outcomes of the study will be cardiovascular events (heart attack, stroke or dying as a result of cardiovascular disease), as well as new or worsening diabetic eye and kidney disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesAustralia, Canada, China, Netherlands, United Kingdom
CollaboratorsInstitut de Recherches Internationales Servier, University of Sydney, National Health and Medical Research Council, Australia

Timeline

Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 5, 2005
Enrollment StartJun 1, 2001
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 20.8 years ago

Interventions

Perindopril-indapamidedrug

Gliclazide MR-based glucose loweringdrug